Results 41 to 50 of about 180 (146)
Advance of second-line chemotherapy in advanced non-small cell lung cancer
Chinese Journal of Lung Cancer, 2008 There is a temporal disease-free period after 1st line chemotherapy in advanced non-small cell lung cancer (NSCLC), most of patients need 2nd line chemotherapy.
Li ZHANG
doaj
Advanced Biology, EarlyView.Extracellular vesicles (EVs) play a dual role in diagnostics and therapeutics, offering innovative solutions for treating cancer, cardiovascular, neurodegenerative, and orthopedic diseases. This review highlights EVs’ potential to revolutionize personalized medicine through specific applications in disease detection and treatment.
Farbod Ebrahimi +4 more
wiley +1 more source
Sequential dose-dense single agent chemotherapy for locally advanced breast cancer [PDF]
Archive of Oncology, 2003 Chemotherapy of breast cancer is still the area of intensive research. Based on mathematical model of tumor cell growth kinetics, articulated by Larry Norton, novel concept of chemotherapy in breast cancer was launched and it implies dose-densification ...
Vrbić Svetislav +3 more
doaj +1 more source
Advanced Functional Materials, EarlyView.Hyaluronic acid‐dopamine‐based intra‐crosslinked microsphere including cisplatin (HPC MS) is fabricated by spray‐drying and calcium/iron ions are introduced for interparticle crosslinking. Designed microsphere‐aggregated hydrogel (MAH) system including cisplatin/CaO2/FeSO4 can provide apoptosis/calcicoptosis/ferroptosis‐mediated chemo/cascade ...
ChaeRim Hwang +6 more
wiley +1 more source
Advanced Functional Materials, EarlyView.The Angiopep‐2 peptide density on polymeric nanoparticles significantly impacts blood–brain barrier (BBB) penetration. This study explores this nuanced relationship using various in vitro models and in vivo assays, revealing that dynamic models better predict BBB penetration.
Weisen Zhang +9 more
wiley +1 more source
Diferenças no tratamento sistêmico do câncer no Brasil: meu SUS é diferente do teu SUS
Brazilian Journal of Oncology, 2017 Objetivo: Identificar diferenças no tratamento sistêmico dos quatro tipos mais incidentes de câncer tratados no SUS e comparar os tratamentos oferecidos com as Diretrizes Terapêuticas (DTs) estabelecidas pelo Ministério da Saúde (MS), assim ...
Rafael Aliosha Kaliks +3 more
doaj +1 more source
H2O2‐Generating Advanced Nanomaterials for Cancer Treatment
Advanced Functional Materials, EarlyView.H2O2‐generating nanoplatforms can exploit tumor redox imbalance for O2 and toxic reactive oxygen species generation, leading to hypoxia reversal, and apoptosis of cancer cells, respectively. This review highlights the mechanisms of these nanoplatforms, including exogenous H₂O₂ delivery, endogenous amplification, and metal peroxides, which leads to ...
Kiyan Musaie +8 more
wiley +1 more source
Advanced Functional Materials, EarlyView.This review highlights recent advances in engineering artificial antigen‐presenting cells (aAPCs) as alternatives to dendritic cells for T cell expansion. Key design principles inspired by the immunological synapse are discussed, with emphasis on strategies for polyclonal and antigen‐specific T cell expansion.
Nguyen Thi Nguyen, Yu Seok Youn
wiley +1 more source
Advanced Functional Materials, EarlyView.Zr‐Fe MOF@Ribociclib@Herceptin (ZFRH) efficiently targets/kills Human Epidermal Growth Factor Receptor 2/Estrogen Receptor‐positive (HER2/ER+) breast cancer cells. It combats tumors by: 1) Elevating ROS, altering redox balance; 2) Inhibiting transcription; 3) Inducing pyroptosis.
Hongkun Miao +8 more
wiley +1 more source
Advanced Healthcare Materials, EarlyView.This perspective provides an overview of the growing interest in utilizing various gasotransmitters—small gaseous signaling molecules namely nitric oxide (NO), carbon monoxide (CO), and hydrogen sulfide (H2S)—for several therapeutic applications, with emphasis on the potential use of porous materials as carriers to provide safe and controlled local ...
Rosana V. Pinto +2 more
wiley +1 more source